1. All Products
  2. AMPHOTERICIN B liposomal complex, 50mg, powder, vial
Public Pricelist

AMPHOTERICIN B liposomal complex, 50mg, powder, vial

https://medicalguidelines.msf.org/en/node/740
https://unicat.msf.org/cat/product/11617
STD DINJAMBL5V-

Valid Article

Former Code(s): -X DINJAMPH5V-
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
6.3 - Antifungal medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.5.2 - Antileishmaniasis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J02AA01
Anatomical Therapeutic Chemical Classification according to WHOCC
PE
The order of this product needs to be justified and is only acceptable under certain conditions.
CT25
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/571722/image_1920?unique=2563e7c

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

AMPHOTERICIN B liposomal

Therapeutic Action

Antifungal medicine

Indications

Cryptococcal meningitis, when conventional amphotericin B is contra-indicated.

Cutaneomucous or visceral leishmaniasis

Severe histoplasmosis

Some restricted information has been hidden. Sign in to see this information

Instructions for use

  • Reconstitute the powder vial with 12 ml of water for injection to obtain a concentrated solution at 4 mg/ml amphotericin B.
  • Using a syringe, withdraw the required dose of concentrated solution.
  • Attach the filter provided with the vial to the syringe.
  • Through the filter, inject the contents of the syringe, into the required volume of 5% glucose (50, 250 or 500 ml) to obtain a solution for IV infusion between 0.2 and 2 mg/ml amphotericin B.

The liposomal amphotericin B (AmBisome®) is better absorbed and has less risk of renal toxicity than the conventional amphotericin B (Fungizone®) for the treatment of cryptococcal meningitis.

Storage

  • Powder: between 2ºC and 25°C. Do not refrigerate. Do not freeze. Protect from sunlight
  • Solutions (concentrated and for infusion): keep refrigerated between 2°C and 8°C for 24hrs maximum. Do not freeze.

(Cf Introduction: Thermosensitive products)